

1-1 By: Landgraf (Senate Sponsor - Sparks) H.B. No. 3057
1-2 (In the Senate - Received from the House May 12, 2025;
1-3 May 13, 2025, read first time and referred to Committee on Health &
1-4 Human Services; May 23, 2025, reported favorably by the following
1-5 vote: Yeas 7, Nays 0; May 23, 2025, sent to printer.)

1-6 COMMITTEE VOTE

	Yea	Nay	Absent	PNV
1-7				
1-8	X			
1-9	X			
1-10	X			
1-11	X			
1-12	X			
1-13	X			
1-14			X	
1-15			X	
1-16	X			

1-17 A BILL TO BE ENTITLED
1-18 AN ACT

1-19 relating to health benefit plan coverage for chimeric antigen
1-20 receptor T-cell therapy.

1-21 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

1-22 SECTION 1. Chapter 1369, Insurance Code, is amended by
1-23 adding Subchapter E-2 to read as follows:

1-24 SUBCHAPTER E-2. COVERAGE FOR CHIMERIC ANTIGEN RECEPTOR T-CELL
1-25 THERAPY

1-26 Sec. 1369.221. APPLICABILITY OF SUBCHAPTER. (a) This
1-27 subchapter applies only to a health benefit plan that provides
1-28 benefits for medical or surgical expenses incurred as a result of a
1-29 health condition, accident, or sickness, including an individual,
1-30 group, blanket, or franchise insurance policy or insurance
1-31 agreement, a group hospital service contract, or an individual or
1-32 group evidence of coverage or similar coverage document that is
1-33 issued by:

- 1-34 (1) an insurance company;
1-35 (2) a group hospital service corporation operating
1-36 under Chapter 842;
1-37 (3) a health maintenance organization operating under
1-38 Chapter 843;
1-39 (4) an approved nonprofit health corporation that
1-40 holds a certificate of authority under Chapter 844;
1-41 (5) a multiple employer welfare arrangement that holds
1-42 a certificate of authority under Chapter 846;
1-43 (6) a stipulated premium company operating under
1-44 Chapter 884;
1-45 (7) a fraternal benefit society operating under
1-46 Chapter 885;
1-47 (8) a Lloyd's plan operating under Chapter 941; or
1-48 (9) an exchange operating under Chapter 942.

1-49 (b) Notwithstanding any other law, this subchapter applies
1-50 to:

- 1-51 (1) a small employer health benefit plan subject to
1-52 Chapter 1501, including coverage provided through a health group
1-53 cooperative under Subchapter B of that chapter;
1-54 (2) a standard health benefit plan issued under
1-55 Chapter 1507;
1-56 (3) a basic coverage plan under Chapter 1551;
1-57 (4) a basic plan under Chapter 1575;
1-58 (5) a primary care coverage plan under Chapter 1579;
1-59 (6) a plan providing basic coverage under Chapter
1-60 1601; and
1-61 (7) a self-funded health benefit plan sponsored by a

professional employer organization under Chapter 91, Labor Code.

Sec. 1369.222. EXCEPTIONS TO APPLICABILITY OF SUBCHAPTER.
This subchapter does not apply to an issuer or provider of health
benefits under or a pharmacy benefit manager administering pharmacy
benefits under:

(1) the state Medicaid program, including the Medicaid
managed care program under Chapter 540, Government Code; or

(2) the child health plan program under Chapter 62,
Health and Safety Code.

Sec. 1369.223. COVERAGE REQUIREMENTS. A health benefit
plan that provides coverage for chimeric antigen receptor T-cell
therapy must provide coverage for chimeric antigen receptor T-cell
therapy that is:

(1) medically necessary; and

(2) administered by a health care provider that is:

(A) qualified as a certified health care facility
in accordance with the procedure for the chimeric antigen receptor
T-cell therapy product license approved by the United States Food
and Drug Administration; and

(B) participating in the health benefit plan's
network with respect to any other service.

Sec. 1369.224. RULES. The commissioner shall adopt rules
as necessary to administer this subchapter.

SECTION 2. This Act applies only to a health benefit plan
delivered, issued for delivery, or renewed on or after January 1,
2026.

SECTION 3. This Act takes effect September 1, 2025.

* * * * *